SVA: A modern solution to an uncomfortable problem

Incontinence is more than an uncomfortable topic - it's a booming global problem traditionally managed at high cost for aged care providers. Simavita's (ASX: SVA) SIM system is the first of its kind to create evidence-based care plans for incontinence sufferers – delivering significant patient and cost benefits. New pilot programs and increasing sales are fueling interest in the digital healthcare company with Hong Kong-based fund manager Ward Ferry taking a cornerstone position in Simavita as it seeks to raise up to $8.2 million. Darren Vincent, Research Analyst at Shaw Stockbroking, says the sector is seeing a renaissance of investor interest. "6 - 12 months ago we couldn't get any interest. However, the success of stories like Nanosonics and Impedimed have got people trying to work out which company will be next." In his latest note, Darren highlights recent progress being made by Simavita and shares his target price and recommendation. Access the research here: (VIEW LINK)